BRIEF: CSPC Pharma profit dips on falling drug revenue

1093.HK

CSPC Pharmaceutical Group Ltd. (1093.HK) warned on Thursday that is net profit for the first nine months of this year fell about 16% compared with a year earlier.

It blamed the decline on falling revenue for its oncology and cardiovascular therapeutic drugs, which were down about 18% and 11%, respectively, year-on-year during the period. Those declines were partially offset by a 4% rise in revenue from its nervous system therapeutic drug sales. CSPC’s shares fell 13% to HK$5 in early Friday trade.

By A. Au

To subscribe to Bamboo Works free weekly newsletter, click here

,

Related Articles

RELATED ARTICLES

  1. Earnings blow for CSPC Pharma
    Earnings blow for CSPC Pharma as the state drives a hard bargain
    1093.HK
  2. Hengrui Pharma accelerates bid for global brand status
    600276.SHG
  3. Dida reverses into revenue contraction, falling profits
    2559.HK
  4. ZG Group set to forge Hong Kong’s second De-SPAC listing
    2572.HK
  5. Mixue pours up strong growth in China’s overheated bubble tea market
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

Recent Articles

Agora makes real time engagement technology

AI powers Agora back to revenue growth

The maker of real-time engagement technology is benefitting from new demand for products like real-time online virtual tutors and talking toys Key Takeaways: Agora reported a slight revenue increase in…
API.US